Research Validates Relevance of DMX Receptor-HIT Technology
Filed with ASX · · 3 pages · English
Earlier from Dimerix
- Investor Update
- Receipt of $420k Research & Development Tax Refund
- Corporate Presentation
- Key Patent Allowed in Japan
- Dimerix Raises $2 million to Advance Clinical Program
Later from Dimerix
- Positive Results from Phase 2a Trial of DMX-200
- DMX-200 tablet manufacture and human study timeline
- Notice of Annual General Meeting/Proxy Form
- Dimerix Receives $545k R&D Tax Refund
- Ethics Committee Approval for Pharmacokinetic Trial
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix